Approval for Oral Pulmonary Arterial Hypertension Treatment

Orenitram (treprostinil) by United Therapeutics (UTHR) is an oral treatment for Pulmonary Arterial Hypertension (PAH) that belongs to the prostacyclin receptor (IP receptor) agonist class. It initially received FDA approval on December 20, 2013, offering a significant convenience for patients who previously relied on injectable or inhaled formulations. The FDA's initial approval, based on New Drug Application (NDA 203496), was for use as a single therapy to improve exercise ability. The launch of this oral formulation marked a pivotal moment, revolutionizing existing treatment pathways and maximizing patient convenience.

Expanded Indication Through Phase 3 FREEDOM-EV Trial

Despite initial market challenges, United Therapeutics achieved a breakthrough with the Phase 3 FREEDOM-EV (NCT01560624) trial. This trial evaluated the efficacy of Orenitram in combination with existing oral single therapy in 690 patients. The results demonstrated a remarkable 26% reduction in the risk of disease progression and mortality compared to the placebo group. Based on this compelling efficacy data, the FDA approved the label expansion in October 2019, recognizing its effect in delaying disease progression.

Leading Position in the Global PAH Market

The global PAH market is estimated to be worth approximately $6.9 billion to $8 billion by 2025 and is experiencing steady growth. Orenitram has established itself as a key component of United Therapeutics' portfolio within this large market, generating annual revenue of $496.9 million in 2025. This represents a 14% increase year-over-year, driven in part by increased commercial utilization following changes to the U.S. Medicare Part D program. Despite the presence of strong competitors such as Uptravi (selexipag) from Johnson & Johnson (J&J), Orenitram continues to solidify its unique market position.

Continued Growth Potential and Future Outlook

The updated regulatory data and continued growth of Orenitram have a very positive impact on the long-term corporate value of United Therapeutics. In particular, as its value as a combination therapy has been proven, prescription recommendations have been upgraded, leading to increased prescriptions. It is expected to achieve both of the goals of improving survival rates and improving long-term quality of life for PAH patients. From an investor's perspective, it is necessary to continuously monitor the patent expiration schedule and the clinical results of competing pipelines.